Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Bariatric Surgery in Children. (BASIC)

25 août 2021 mis à jour par: Maastricht University Medical Center

The BASIC Trial. Morbid Obesity in Children and Adolescents: a Prospective Randomised Trial of Conservative Treatment Versus Surgery

Rationale:

In the Western world overweight and obesity is an increasing problem both in adults and in children. In youth, it is associated with early death and a number of co-morbidities including metabolic and endocrine changes, increased inflammatory status, cardiovascular abnormalities, nonalcoholic fatty liver disease, and impaired quality of life.

The standard treatment for morbid obesity in children is by combined life style interventions. However, the medium and long term effects of dietetic interventions, behaviour therapy and medication is relatively poor. In adults bariatric surgery shows good results with up to 30% weight reduction in 3 years. The preliminary results in youth are similar, but surgery in this age group is relatively uncommon. In the Netherlands surgery in this age group is only allowed in clinical trials, until the benefits and risks have been established. (National Health Authorities)

Objective:

To determine if surgery gives a superior weight and body mass index (BMI) reduction than combined life style interventions in adolescents with morbid obesity and to assess its effect on obesity associated co-morbidity.

Study design:

Prospective randomised interventional study.

Study population:

Morbidly obese children, aged 14 - 16 years, with sex and age adjusted BMI >40 kg/m2 or >35 kg/m2 with co-morbidity.

Intervention:

Bariatric surgery by laparoscopic adjustable gastric band (LAGB) or combined life style interventions

Main study parameters/endpoints:

Primary endpoints: weight loss, loss of excess weight, loss of excess BMI. Secondary endpoints: Body composition, pubertal development, metabolic and endocrine changes, inflammatory status, cardiovascular abnormalities, non-alcoholic steatohepatitis, brain development, quality of life, and behaviour changes. The potential complications of surgery are monitored.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Réel)

60

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Limburg
      • Maastricht, Limburg, Pays-Bas, 6202ZA
        • Maastricht University Medical Center

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

14 ans à 16 ans (Enfant)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Aged 14 to 16
  • Age and sex adjusted BMI >40 kg/m2 or >35 kg/m2 with associated co-morbidity.

    * Associated co-morbidity includes: glucose intolerance, type 2 diabetes, hypertension, pseudotumor cerebri, acanthosis nigricans, obstructive sleep apnoea syndrome, depression, arthropathies, non-alcoholic steatohepatitis and dyslipidemia.

  • > 1 year multidisciplinary organized weight reducing attempts with less than 5% weight loss
  • Demonstrate decisional capacity

Exclusion Criteria:

  • Psychologically not suitable
  • Pre-menarche or bone age <15 years in boys
  • Obesity associated to other disorders such as hypothyroidism
  • Syndromal disorders such as Prader-Willi syndrome
  • Severe cardiorespiratory impairment (ASA class 3 or higher)
  • Insufficiently fluid in the Dutch language
  • Unwillingness to adhere to follow-up programmes

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Groupe de contrôle
Control group will receive standard therapy consisting of combined lifestyle interventions.
Expérimental: Laparoscopic adjustable gastric band
Laparoscopic gastric band placement. Combined lifestyle interventions will continue after surgery.
Control group will receive standard therapy consisting of combined lifestyle interventions.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Weight
Délai: 6 months
Weight loss, excess weight loss and loss of excess BMI.
6 months
Weight
Délai: 12 months
Weight loss, excess weight loss and loss of excess BMI.
12 months
Weight
Délai: 24 months
Weight loss, excess weight loss and loss of excess BMI.
24 months
Weight
Délai: 36 months
Weight loss, excess weight loss and loss of excess BMI.
36 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Body composition
Délai: 12 months
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
12 months
Pubertal development
Délai: 6 months
Follow-up of hormonal status and Tanner stages.
6 months
Metabolic and endocrine changes
Délai: 6 months
6 months
Inflammatory status
Délai: 6 months
Measurement of serum inflammatory markers.
6 months
Cardiovascular abnormalities
Délai: 6 months
6 months
Non-alcoholic fatty liver disease
Délai: 6 months
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured. CCL-2 is used as a surrogate marker to assess liver disease.
6 months
Quality of life changes
Délai: 6 months
6 months
Behaviour changes
Délai: 6 months
Measuring impulsivity and positive reward dominance with a computer task.
6 months
Operative complications
Délai: up to 36 months
Early and late complications are being monitored
up to 36 months
Effects on sleep architecture
Délai: 6 months
6 months
Brain development
Délai: 6 months
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
6 months
Body composition
Délai: 24 months
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
24 months
Body composition
Délai: 36 months
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
36 months
Pubertal development
Délai: 12 months
Follow-up of hormonal status and Tanner stages.
12 months
Pubertal development
Délai: 24 months
Follow-up of hormonal status and Tanner stages.
24 months
Pubertal development
Délai: 36 months
Follow-up of hormonal status and Tanner stages.
36 months
Metabolic and endocrine changes
Délai: 12 months
12 months
Metabolic and endocrine changes
Délai: 24 months
24 months
Metabolic and endocrine changes
Délai: 36 months
36 months
Inflammatory status
Délai: 12 months
Measurement of serum inflammatory markers.
12 months
Inflammatory status
Délai: 24 months
Measurement of serum inflammatory markers.
24 months
Inflammatory status
Délai: 36 months
Measurement of serum inflammatory markers.
36 months
Cardiovascular abnormalities
Délai: 12 months
12 months
Cardiovascular abnormalities
Délai: 24 months
24 months
Cardiovascular abnormalities
Délai: 36 months
36 months
Non-alcoholic fatty liver disease
Délai: 12 months
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured. CCL-2 is used as a surrogate marker to assess liver disease.
12 months
Non-alcoholic fatty liver disease
Délai: 24 months
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured. CCL-2 is used as a surrogate marker to assess liver disease.
24 months
Non-alcoholic fatty liver disease
Délai: 36 months
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured. CCL-2 is used as a surrogate marker to assess liver disease.
36 months
Quality of life changes
Délai: 12 months
12 months
Quality of life changes
Délai: 24 months
24 months
Quality of life changes
Délai: 36 months
36 months
Effects on sleep architecture
Délai: 12 months
12 months
Effects on sleep architecture
Délai: 24 months
24 months
Effects on sleep architecture
Délai: 36 months
36 months
Behaviour changes
Délai: 12 months
Measuring impulsivity and positive reward dominance with a computer task.
12 months
Behaviour changes
Délai: 24 months
Measuring impulsivity and positive reward dominance with a computer task.
24 months
Behaviour changes
Délai: 36 months
Measuring impulsivity and positive reward dominance with a computer task.
36 months
Brain development
Délai: 12 months
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
12 months
Brain development
Délai: 24 months
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
24 months
Brain development
Délai: 36 months
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
36 months
Physical activity
Délai: 6 months
Assessment of physical activity using a questionnaire and an accelerometer.
6 months
Physical activity
Délai: 12 months
Assessment of physical activity using a questionnaire and an accelerometer.
12 months
Physical activity
Délai: 24
Assessment of physical activity using a questionnaire and an accelerometer.
24
Physical activity
Délai: 36 months
Assessment of physical activity using a questionnaire and an accelerometer.
36 months
Behavior towards food
Délai: 6 months
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
6 months
Behavior towards food
Délai: 12 months
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
12 months
Behavior towards food
Délai: 24 months
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
24 months
Behavior towards food
Délai: 36 months
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
36 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: LWE van Heurn, Professor, Maastricht University Medical Center
  • Chercheur principal: Yvonne Roebroek, PhD Student, Maastricht University Medical Center
  • Chercheur principal: Givan F Paulus, PhD Student, Spaarne Gasthuis, Haarlem

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 décembre 2011

Achèvement primaire (Anticipé)

1 décembre 2022

Achèvement de l'étude (Anticipé)

1 décembre 2022

Dates d'inscription aux études

Première soumission

22 juillet 2010

Première soumission répondant aux critères de contrôle qualité

29 juillet 2010

Première publication (Estimation)

30 juillet 2010

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

26 août 2021

Dernière mise à jour soumise répondant aux critères de contrôle qualité

25 août 2021

Dernière vérification

1 août 2021

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • NL26279.068.09

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

3
S'abonner